Welcome to our dedicated page for Autolus Therapeutics news (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on Autolus Therapeutics stock.
Autolus Therapeutics plc reports news on its commercial-stage biopharmaceutical business developing, manufacturing and delivering next-generation programmed T cell therapies. Updates center on AUCATZYL (obecabtagene autoleucel, or obe-cel), product revenue, manufacturing capacity, gross margin plans and the company’s acute lymphoblastic leukemia business.
Company announcements also cover clinical programs using obe-cel and related T cell therapy candidates in pediatric relapsed/refractory acute lymphoblastic leukemia, lupus nephritis and progressive multiple sclerosis. Other recurring items include financial results, operational efficiency actions, investor presentations, Nasdaq inducement equity grants and ADR-related public-company disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Autolus Therapeutics has announced that the pivotal Phase 2 FELIX study for its CAR T cell therapy, obecabtagene autoleucel (obe-cel), will be presented at the 2023 ASCO Annual Meeting from June 2-6 in Chicago. The oral presentation, titled “Safety and efficacy of Obecabtagene autoleucel in relapsed/refractory adult B-Cell acute lymphoblastic leukemia”, highlights the efficacy of obe-cel in treating hard-to-treat adult B-cell Acute Lymphoblastic Leukemia. This investigational therapy aims to address the limitations of existing CD19 CAR T cell therapies. The trial is designed to enroll approximately 100 patients across top centers in the US, UK, and Europe with a primary endpoint of overall response rate. Autolus is also targeting the submission of a Biologics License Application by the end of 2023.
Autolus Therapeutics plc (Nasdaq: AUTL) has appointed Cardinal Health (NYSE: CAH) to facilitate the U.S. commercialization of its CAR T-cell therapies. This partnership includes a depot model for improved delivery efficiency, allowing the product to be positioned closer to treatment sites while awaiting final release. Cardinal Health will also assist with order-to-cash operations. Autolus is preparing to file a Biologics License Application (BLA) for its investigational therapy, obe-cel, by the end of 2023, with key data from the pivotal FELIX study to be presented at upcoming conferences in June. This effort aims to enhance patient access to innovative cancer therapies.
Autolus Therapeutics (Nasdaq: AUTL) announced a significant advancement in T-cell engineering with the publication of research that enhances CAR T-cell efficacy against solid tumors by preventing apoptosis caused by Fas ligand. The study, detailed in Molecular Therapy Nucleic Acids, highlights the development of Fas-TNFR chimeras that not only inhibit FasL-mediated cell death but also stimulate CAR T-cell proliferation. Among these, the Fas-CD40 fusion was noted for its effectiveness in improving anti-tumor response in FasL presence. This research expands Autolus' toolkit against complex cancers and aligns with its strategy to enhance T-cell therapy applications, particularly for solid tumors. The findings position Autolus as a key player in advancing cancer treatment through targeted therapies.
Autolus Therapeutics (Nasdaq: AUTL) announced positive updated data for its AUTO1/22 study in pediatric B-cell Acute Lymphoblastic Leukemia (B-ALL) at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation. The study demonstrated that AUTO1/22 effectively targets both CD19 and CD22 antigens, addressing CD19 negative relapse, a common treatment failure after CAR T cell therapy.
Among the 12 patients treated, 83% achieved minimal residual disease negative complete response, including 66.7% of patients with CD19 negative disease. Importantly, there were no severe cytokine release syndrome cases, and no relapses or emergence of minimal residual disease related to antigen escape were observed after a median follow-up of 8.7 months. This demonstrates the potential of AUTO1/22 in enhancing treatment efficacy and safety for pediatric B-ALL patients.